InSilico Medicine’s $255 Million Series C Financing

Wilson Sonsini Goodrich & Rosati advised InSilico Medicine on the deal. Ashurst represented Mirae Asset Capital.

Hong Kong-based InSilico Medicine, a global leader in end-to-end artificial intelligence for target discovery, small molecule chemistry, and clinical development, announced that it has closed a $255 million Series C financing led by Warburg Pincus. The financing included participation by current investors including Qiming Venture Partners, Pavilion Capital, Eight Roads Ventures, Lilly Asia Ventures, Sinovation Ventures, BOLD Capital Partners, Formic Ventures, and Baidu Ventures and new investors including CPE, Hillhouse Capital, OrbiMed, Mirae Asset, B Capital Group, Deerfield Management, Maison Capital, Lake Bleu Capital, President International Development Corporation, Sequoia Capital China, and Sage Partners.

Proceeds from the financing will be used to progress InSilico Medicine’s current therapeutic programs into human clinical trials, initiate multiple new programs for novel and difficult targets, and further develop its AI and drug discovery capabilities.

The Wilson Sonsini team that represented InSilico Medicine in this transaction included: Jie Zhu (Picture), Barry Taylor, Xuchao Dong, Helen Wang, TJ Tingjie Li, Yiwen Feng, Jonathan Zhu, Nika Antonikova, Karen Wong, Michael Hostetler, Scott L. Burkette, Bo Chen, Stephen R. Heifetz, David M. Hoffmeister, Eva F. Yin and Sriram Krishnamurthy.

The Ashurst team was led by partner Frank Bi, supported by Roger Dong and Jessica Leung.

Involved fees earner: Frank Bi – Ashurst; Roger Dong – Ashurst; Jessica Leung – Ashurst; Nika Antonikova – Wilson Sonsini Goodrich & Rosati; Scott Burkette – Wilson Sonsini Goodrich & Rosati; Bo Chen – Wilson Sonsini Goodrich & Rosati; Xuchao Dong – Wilson Sonsini Goodrich & Rosati; Yiwen Feng – Wilson Sonsini Goodrich & Rosati; Stephen Heifetz – Wilson Sonsini Goodrich & Rosati; David Hoffmeister – Wilson Sonsini Goodrich & Rosati; Michael Hostetler – Wilson Sonsini Goodrich & Rosati; Sriram Krishnamurthy – Wilson Sonsini Goodrich & Rosati; Barry Taylor – Wilson Sonsini Goodrich & Rosati; TJ Tingjie Li – Wilson Sonsini Goodrich & Rosati; Helen Wang – Wilson Sonsini Goodrich & Rosati; Karen Wong – Wilson Sonsini Goodrich & Rosati; Eva Yin – Wilson Sonsini Goodrich & Rosati; Jie Zhu – Wilson Sonsini Goodrich & Rosati; Jonathan Zhu – Wilson Sonsini Goodrich & Rosati;

Law Firms: Ashurst; Wilson Sonsini Goodrich & Rosati;

Clients: InSilico Medicine; Mirae Asset Capital;

Author: Sonia Carcano